ArticlePloS one2026
Comparison of the effects of different types of treatment protocols on the median and overall survival rates of non-small cell lung cancer patients: A real-world retrospective study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer treatment presents a major challenge globally. The advent of monoclonal antibodies (mAbs) has ushered in a new era in the treatment of non-small cell lung cancer (NSCLC). This study aimed to investigate the impact of the addition of mAbs to platinum-based doublet therapy on overall survival in NSCLC patients and the difference in median survival among patients treated with different treatment protocols. In this study, demographic, clinical, and therapeutic data from 359 NSCLC patients were recorded, and the histopathological and disease stages of the patients, along with the site of metastasis, were documented. The median survival rates, 1-, 3-, and 5-year survival rates, covariate hazard ratios, and independent predictors of overall survival were analyzed. Statistically significant differences were observed in the median survival of patients treated with different treatment protocols (p = 0.002). Comparing therapies, patients treated with carboplatin/paclitaxel+anti-PD-1/anti-PD-L1 mAb or cisplatin/vinorelbine+anti-PD-1/anti-PD-L1 mAb had highest median survival (median survival months ± SE) (49.4 months ± 9.15 and 34.9 months ± 8.61 respectively) with lowest hazard ratio (HR = 0.032; 95% confidence interval (CI) [0.003-0.310], p = 0.003 and HR = 0.048; 95% CI [0.005-0.465], p = 0.0083 respectively). Patients treated with triple therapy [platinum-based doublet chemotherapy combined with mAb drugs had significantly (p = 0.01) greater median survival (20.7 months ± 3.11; HR = 0.593; 95% CI [0.443-0.794], p = 0.00046) compared to patients treated with platinum-based doublet chemotherapy with concurrent radiation (13.6 months ± 3.8; HR = 0.742 95% CI, [0.531-1.035], p = 0.07884] or patients treated with platinum-based doublet chemotherapy (9.1 months ± 0.68; HR = 1) or single treatment (12.9 months ±3.81; HR = 0.927; 95% CI [0.629-1.365], p = 0.69970) and better 1-, 3-, and 5-year survival rates (95% CI) [66.20% (0.554-0.77), 26.40% (0.162-0.366), and16.25% (0.065-0.261) respectively] than patients treated with platinum-based doublet chemotherapy with concurrent radiation [54% (0.403-0.677), 22% (0.104-0.336), and 4% (0.001-0.079) respectively] or without concurrent radiation [39.10% (0.324-0.458), 12.80% (0.081-0.175) and 3.57% (0.012-0.381) respectively] or single treatment [51.50% (0.407-0.623), 12.12% (0.0193-0.223), and 10.12% (0.003-0.199) respectively]. The statistically significant predictors for overall survival were cancer metastasis (p = 0.0001), disease stage at diagnosis (p = 0.001), patient age (p = 0.017), and performance of lung resection surgery (p = 0.021). 64.1% of the patients had metastasis, and they had significantly lower median survival than patients without metastasis (p = 0.0001). Multi-organ metastasis was the most common type of metastasis (20.9%). In conclusion, the addition of mAbs such as anti-programmed cell death protein 1/programmed death-ligand 1 or epidermal growth factor receptor inhibitors or vascular endothelial growth factor inhibitors to platinum-doublet chemotherapy markedly improved the overall survival and survival rates of NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.